Today, Exact Sciences Corp., renowned for its cancer screening and diagnostic solutions, unveiled the introduction of the Riskguard™ hereditary cancer test across the United States. This innovative test furnishes personalized…
Orca Bio, a biotech firm advancing precise cell therapies for cancer, autoimmune disorders, and genetic blood conditions, has unveiled promising results for its lead investigational therapy, Orca-T, at the 2024…
The College of American Pathologists (CAP) updated the “Principles of Analytic Validation of Immunohistochemical Assays” guideline to provide increased precision and accuracy of clinical immunohistochemical assays. This update assesses evidence…
The MANDARA Phase III trial published in the New England Journal of Medicine and presented at the AAAAI Annual Meeting reveals promising outcomes for FASENRA® (benralizumab) in treating EGPA. This…
Biote Corp. (NASDAQ: BTMD), a leader in personalized hormone optimization and therapeutic wellness, has announced a binding term sheet with Dr. Gary S. Donovitz, Biote’s founder and stockholder, to settle…
United Therapeutics Corporation (Nasdaq: UTHR) has initiated legal action against the United States Food and Drug Administration (FDA), as announced today. The litigation centers on United Therapeutics’ claim that the…
FDA Clears Xolair as Sole Treatment for Food Allergies in Children and Adults Genentech, a member of the Roche Group, disclosed today that the U.S. Food and Drug Administration (FDA)…
TAGRISSO® and Chemotherapy Combo Approved for EGFR-Mutated Lung Cancer AstraZeneca’s TAGRISSO® (osimertinib) combined with chemotherapy has secured approval in the US for treating adult patients with locally advanced or metastatic…
Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and its parent company, Otsuka Pharmaceutical Co., Ltd. (Otsuka), have disclosed the topline findings from the phase 3 clinical trial of AVP-786 aimed…
Medpace Holdings, Inc. (Nasdaq: MEDP) has released its financial results for the fourth quarter and full year ending December 31, 2023. Fourth Quarter 2023 Financial Highlights: Full Year 2023 Financial…
Following our previous update on January 5, 2024, we are delighted to share the latest advancements with you. A Phase I dose-ranging clinical trial investigating DFP-14927 in patients with solid…
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology firm specializing in small molecule drugs within virology and immunology, has released its financial results for the fiscal first quarter ending December…